Today's Healthcare Pulse
Abridge teams with Eli Lilly and Nvidia to expand AI scribe platform
Abridge announced a strategic investment from Eli Lilly and a partnership with Nvidia to build a foundation model for clinical conversations. The collaboration aims to broaden Abridge’s AI‑scribe services across more health systems and integrate with payers. The company already supports over 300 health systems.
Also developing:
STAT+: For Pancreatic Cancer Patients, an Exciting Drug Can Feel Out of Reach
Revolution Medicines' experimental drug daraxonrasib, which nearly doubled overall survival for pancreatic cancer patients in a recent trial, is now being distributed through an expanded access program. The therapy is positioned as a potential second‑line treatment, offering hope for patients who have exhausted standard options. However, the small biotech’s limited manufacturing capacity and the administrative complexity of the program have created uncertainty about when and to whom the drug will be available.
Genomic Testing Gaps, Chemotherapy Decisions in Young Women With HR+ Breast Cancer: Mitali Shah, MD
A new analysis of women under 50 with hormone‑receptor‑positive breast cancer shows that many receive chemotherapy despite low Oncotype DX recurrence scores. The study links chemo use to higher tumor stage, poor grade, and node involvement, highlighting a gap between genomic...
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
CMS Administrator Mehmet Oz used a June 2 White House briefing to announce a major expansion of the TrumpRx price‑transparency platform, adding 160 drugs to bring the catalog to roughly 750 items and reporting 12 million visitors and $500 million in consumer savings. He...
Reassurance for Bladder Cancer Patients | Letters
Doctors are touting a new drug under trial that could eliminate the need for radical cystectomy in bladder‑cancer patients. Early-phase data indicate the therapy can shrink tumors enough to preserve bladder function, offering a less invasive alternative to surgery. Current...
Trump’s Cruel Medicaid Work Requirements: Can States Mitigate the Damage?
The Trump administration released a 400‑page proposal that tightens Medicaid work‑requirement rules under the One Big Beautiful Bill Act. Disabled and medically complex adults must now document their inability to work, even for conditions like cancer or end‑stage renal disease. The rules, slated for...
NMDP Celebrates Public-Private Partnership with HRSA in Expanding Patient Access to Life-Saving Bone Marrow and Cord Blood Transplant
The National Marrow Donor Program (NMDP) and the Health Resources and Services Administration (HRSA) marked a milestone of 150,000 life‑saving bone marrow and cord blood transplants under the C.W. Bill Young Cell Transplantation Program. The partnership, backed by federal funding...
More Americans Own Wearables, Connected Health Devices: Survey
A recent Rock Health survey of 8,000 Americans finds nearly 60% of U.S. adults now own at least one wearable or connected health device such as an Apple Watch, Oura Ring, or continuous glucose monitor. Ownership has surged from 13%...
Novo Nordisk Backs Enobosarm, Canaccord Sets $25 Target
Canaccord note out on on $VERU (from earlier) - BUY rating and $25 Price TGT "Supply agreement with Novo Nordisk shows Big Pharma players in obesity are watching enobosarm play out clinically" We view this as...
Med
New @nberpubs: "An Unfunded Mandate? Medicaid Continuous Coverage Requirements and State Fiscal Burdens During COVID-19" https://t.co/LEqAlzf02u "states’ share of the continuous coverage provision's costs was $139.2 billion, which is roughly $11.0 billion less than the revenues states received"
Tazemetostat
Tazemetostat (Tazverik®) is the first oral EZH2 inhibitor approved by the FDA, initially for epithelioid sarcoma and later for follicular lymphoma with stronger activity in EZH2‑mutant patients. The sarcoma indication showed a modest 15% overall response rate, while the lymphoma...
ACA Cuts Uninsured, Shifts Some to Public Coverage
New @nberpubs: "How Efficient was the Affordable Care Act at Reducing Uninsured Rates?" https://t.co/nj65PfrB3o "For adults with incomes between 151%–400% FPL, each percentage point increase in public coverage was associated with about a 0.6 percentage point decrease in uninsured and a...
Treatment Reactivates Sluggish Healing Genes in Aging Skin
The treatment seemed to wake up healing pathways that are normally sluggish in older tissue. Gene activity increased in areas tied to wound repair, including collagen production, blood vessel growth, tissue remodeling, and other processes needed to close and strengthen...
Kyverna Posts Positive Phase 1 Data for Miv-Cel CAR‑T in Rheumatoid Arthritis
Kyverna Therapeutics announced that its autologous CD19‑targeting CAR‑T candidate miv-cel achieved positive early‑stage outcomes in ACPA‑positive, treatment‑refractory rheumatoid arthritis patients. The data, presented at the EULAR 2026 congress, could mark a new therapeutic avenue for autoimmune disease beyond oncology.
Philips and WellSpan Health Seal 7‑Year Alliance to Deploy AI‑Driven Imaging Across 12 Hospitals
Royal Philips and WellSpan Health announced a seven‑year strategic alliance that makes Philips the preferred vendor for imaging across all 12 WellSpan hospitals, diagnostic centers and ambulatory surgery sites. The partnership includes joint R&D, AI‑enabled workflow tools and a coordinated...
VA Cuts Procurement Delays, Slashing Prosthetic Wait Times by Up to 42%
The Department of Veterans Affairs eliminated most contracting reviews for prosthetic limbs, reducing delivery times by 10 days already and projecting a 42% cut once fully implemented. The change affects up to 380,000 veterans who rely on prosthetic care each...
Alnylam Inks $2 B AI Partnership with Inceptive Nucleics to Speed RNAi Drug Discovery
Alnylam Pharmaceuticals announced a partnership with AI‑driven biotech Inceptive Nucleics valued at up to $2 billion, featuring a $30 million upfront payment. The deal merges Alnylam’s RNA interference platform with Inceptive’s generative AI models to fast‑track nucleic‑acid drug design under Alnylam’s 2030...
Farmagenericos Cuts Pharmacy Procurement Costs 50% with In‑House AI, Serves 6,000+ Stores
Farmagenericos Colombia announced that its proprietary AI procurement engine has lowered drug‑store purchasing costs by an average of 50% for more than 6,000 pharmacies across Colombia and neighboring markets. The speed‑to‑delivery has also dropped to as little as 24 hours,...
What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage
The article argues that price‑transparency efforts have missed the mark by focusing on traditional Medicare, while Medicare Advantage (MA) already provides clearer cost predictability through out‑of‑pocket caps and preset co‑payments. Studies show MA enrollees face 18‑24% lower monthly out‑of‑pocket costs...
Certain Postapproval Requirements and Resources for ANDAs
The FDA released a final Level 2 guidance (Docket FDA‑2017‑D‑6821) to clarify post‑approval requirements for holders of abbreviated new drug applications (ANDAs) under section 505(j) of the FD&C Act. The document outlines statutory and regulatory obligations, points to related guidances, and provides...
3 Deep-Breathing Exercises for Lowering Blood Pressure, According to Experts
High blood pressure affects roughly half of U.S. men and raises heart attack and stroke risk. Experts cite deep‑breathing exercises—diaphragmatic, 4‑7‑8, and slow‑paced breathing—as low‑cost tools that can modestly lower systolic and diastolic readings. A 2023 meta‑analysis of 15 studies...
Lacripep for Neurotrophic Keratitis Gets FDA Designations
TearSolutions' synthetic peptide Lacripep received FDA orphan‑drug and fast‑track designations, clearing a regulatory path for the first‑in‑class therapy for neurotrophic keratitis. The company has dosed the initial cohort in a phase 2 multicenter, randomized trial enrolling about 54 patients who will...
Blood Test Predicts Lung Cancer Risk Years Early
A very impressive study for how we could prevent lung cancer more than 5 years before it is diagnosed. Using machine learning, discovery of a 14-plasma protein signature of risk that predicts responsiveness to an antibody therapy to interleukin, IL-1β Validated...
Where Board-Certified Specialists Choose to Practice: TeleSpecialists Announces Significant 2026 Physician Growth
TeleSpecialists announced it added 44 board‑certified neurologists and psychiatrists in 2026, pushing its specialist network past 200 physicians and marking a 20% year‑over‑year increase. The expanded team now supports more than 400 partner hospitals, delivering 641 thrombolytic administrations each month....
Philips and WellSpan Health Launch 7-Year Strategic AI and Imaging Partnership
Philips and WellSpan Health have signed a seven‑year strategic alliance covering all 12 hospitals, diagnostic centers, and ambulatory surgery sites in Central Pennsylvania and Northern Maryland. The deal makes Philips the preferred vendor for CT, MR, digital X‑ray, ultrasound and...
On a Mission to Standardize Proteomics Workflows
Evosep, a Danish biotech, announced the launch of Evosep Proteomics, an end‑to‑end ecosystem that standardizes sample preparation through Evokit kits and the Lupo system and integrates with its LC‑MS platforms. The solution promises reproducible, low‑variance proteomic data at a target...
Medtronic Seeks Clearance for Hugo Surgical Robot in More Indications
Medtronic announced it has submitted 510(k) applications to expand its Hugo surgical robot into general and gynecologic procedures, adding to the urology clearance it received last year. The new indications would cover the majority of surgeries currently performed with Intuitive’s...
Vida Health Partners with Instacart to Launch Category-Specific Grocery Stipends for Cardiometabolic Care
Vida Health has sealed a nationwide partnership with Instacart to embed category‑specific grocery stipends into its virtual cardiometabolic care model. The program uses Instacart Health Fresh Funds to give members direct financial credits for dietitian‑approved foods, targeting social determinants of...
The Generational Inversion in Employer Health Costs That Most CFOs Aren’t Seeing
Employers are overlooking a hidden driver of rising health costs: employees with a mental‑health diagnosis incur roughly 20% higher spending on chronic disease management, even after excluding psychiatric expenses. The cost gap is most pronounced among Baby Boomers and Gen X,...
STAT+: AI Titans Push Congress for DNA Safeguards
AI pioneers are pressing Congress to adopt robust DNA data safeguards amid growing concerns over genetic privacy. At the same time, transformer co‑creator Jakob Uszkoreit has launched Inceptive Nucleics, a startup that applies foundation‑model AI to RNA‑based therapeutics such as...
"We Are Training NHS Leaders to Be Disappointed"
The BMJ letter argues that NHS leadership programmes invest heavily in training doctors but fail to deliver real authority or protected time, leaving participants ill‑equipped to enact change. While participants gain self‑awareness, the structural constraints of budget cycles, risk appetite,...
Gottlieb Elected to National Academy of Medicine Council
Dr. Scott Gottlieb, senior fellow at the American Enterprise Institute and former FDA commissioner, has been elected to the National Academy of Medicine (NAM) Council, the academy’s governing body. The NAM, part of the National Academies of Sciences, Engineering, and...
An ADC Specialist Sinks on Safety Concerns for Blood Cancer Drug
ADC Therapeutics reported that its antibody‑drug conjugate Zynlonta met the primary endpoint in a Phase 3 trial, extending progression‑free survival by 1.4 months when combined with rituximab. However, the study recorded 27 deaths in the Zynlonta arm versus nine in the...
Palantir "a Point of Weakness" Say MPs Calling to Cut NHS Ties
British MPs have urged the government to invoke the February 2027 break clause in its roughly £330 million (≈ $420 million) NHS contract with US data‑analytics firm Palantir. The Science, Innovation and Technology Committee labeled Palantir’s growing public‑sector footprint a "mismatch with UK...
Massachusetts Expands $125‑Weekly “Food as Medicine” Program, Cutting Hospital Visits by Up to 31%
Massachusetts has broadened its Medicaid‑funded “Food as Medicine” initiative, delivering medically‑tailored meals that cost $125 per person per week. A new Nature Medicine study shows participants experienced 20% fewer emergency department visits and 31% fewer hospitalizations, translating into cost‑neutral or...
AI in Drug Discovery: Surveying the Breadth of the Challenges
The biotech sector is pouring billions into AI for drug discovery, but the payoff hinges on realistic expectations and targeted use cases. Peter Tummino of Nimbus Therapeutics argues AI excels at pattern‑recognition tasks but struggles with novel molecule design and...
This Healthcare Giant Should See Shares Rise on Successful Strategy Shift, Bank of America Says
Bank of America upgraded UnitedHealth Group to Buy, lifting its price target to $450, implying roughly 19% upside. The health insurer’s shares rose 3% in pre‑market trading after the note, adding to a 26% gain over the past year. UnitedHealth’s...
Cutting U.S. Reliance on Chinese Pharma Supply Chains
SCIENCE, SUPPLY CHAINS, GEOECONOMICS, AND POLICY INCENTIVES The Pharma Choke Point: How to Reduce U.S. Dependence on Chinese Pharmaceutical and Biotechnology Supply Chains Important new study from @TomBollyky, @RushDoshi, @Prof_Yadav_SCM & @OliviaWKosloff https://t.co/gyXNs1OSxH
Insurers Reject Coverage for Nipple Tattoo Reconstruction Among Breast Cancer Survivors
Breast cancer survivors are turning to tattoo artists to recreate nipples and areolas after mastectomy, yet a growing number of insurers refuse to cover the procedure. The gap has ignited debate among patient advocates, health‑care providers, and insurers about what...
Melinda French Gates Pledges $215 Million to Boost Global Women’s Health
Philanthropist Melinda French Gates announced a $215 million commitment to expand contraceptive access, maternal health services and menopause research worldwide. The pledge lifts her cumulative women’s‑health donations to more than $600 million in the past two years, signaling a strategic push into...
No One Likes Medicare Advantage | EP 4
In this episode of Healthcare Uncovered, hosts Joe Rotino and Wendell Potter expose how Medicare Advantage—private, for‑profit plans that replace traditional Medicare—cost taxpayers an extra $80‑$140 billion annually while imposing prior authorizations, narrow networks, denials, and up‑coding schemes on patients. Former...
MAIA Gets FDA Clearance to Expand Phase 2 THIO‑101 Lung Cancer Trial
MAIA Biotechnology announced that the U.S. FDA cleared an amendment to its IND, allowing U.S. enrollment for an expanded Phase 2 THIO‑101 trial of ateganosine in non‑small cell lung cancer. The clearance follows fast‑track designation and new manufacturing efficiencies, positioning the...
Del. County EMS Honors Cardiac Arrest Survivors, First Responders
New Castle County honored 52 paramedics, 186 first responders, eight communications staff, 16 police officers and 20 civilians for their roles in 32 lifesaving cardiac‑arrest incidents. The county logged 709 medical cardiac arrests in 2025 with an 11.5% survival rate,...
Pharma Is Betting Big on PD-1/VEGF Bispecifics. But Are Companies Chasing the Wrong Target?
Pharma has poured billions into PD‑1/VEGF bispecific antibodies after ivonescimab outperformed Keytruda in a 2024 lung‑cancer trial. A China‑based phase 3 study showed the drug cut death risk by 34% versus chemotherapy plus a PD‑1 inhibitor, reigniting investor enthusiasm. However, analysts...
Meet Dalton, a New AI-Powered Drug Discovery Platform
DaltonTx, a UK start‑up spun out of AstraZeneca, Exscientia and Oxford, has launched its end‑to‑end AI drug‑discovery platform called Dalton. The system handles data ingestion, model training, molecular design, synthesis and decision‑making, creating a continuous learning engine for both small‑molecule...
Mayo Clinic's At-Home Chemotherapy Signals a New Era in Cancer Care
Mayo Clinic’s Cancer CARE Beyond Walls program lets oncology patients receive chemotherapy, immunotherapy and monitoring at home. Launched in 2023, the initiative combines a central command center, trained home‑health nurses, and an integrated EHR platform to replicate infusion‑center safety. A...
How Measles Came Roaring Back
Measles cases worldwide surged 20% in 2023, reaching 10.3 million, with the United States reporting 1,983 cases. Bangladesh, once hailed for expanding childhood vaccination to over 80%, now faces over 62,000 suspected measles cases and 500 deaths in 2025‑26. The outbreak...
Xbrane Reports the US FDA Acceptance of Resubmitted BLA for Lucamzi (Biosimilar, Lucentis)
Xbrane Biopharma announced that the U.S. FDA has accepted its resubmitted biologics license application for Lucamzi, a biosimilar to Lucentis, and set a BsUFA action date of October 29, 2026. The resubmission, filed in April 2026, addressed the complete response...
Architecture Has a Set of Secret Problems; Other Professions Solved Theirs
The article argues that software architecture lacks the evidence‑based rigor that medicine and structural engineering have adopted. A survey of 222 commonly used patterns revealed that only 39 have more than a single, unverified source, leaving most recommendations on anecdotal...
GLP-1 Receptor Agonists and Increased Risk of Tendon Injury in Athletes
New clinical data presented at the AAOS meeting links GLP‑1 receptor agonists to a roughly 50% increase in serious tendon injuries among athletes, including higher rates of rotator‑cuff, Achilles, peroneal and pectoralis ruptures. The absolute risk remains low—Achilles ruptures rose...
/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/a9/a2/a9a2af7e-39e3-43f1-82d8-829ba51d2f8c/jonas_salk_3.jpg)
When the Fear of Polio Gripped the World, Jonas Salk’s Determination Led to a Liberating Medical Breakthrough
In the early 1950s, Jonas Salk pioneered an inactivated‑virus polio vaccine that defied prevailing belief that only live viruses could confer immunity. After successful animal work, his team launched a massive 1.8 million‑child field trial in 1954, employing double‑blind and observational...